Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 02 tags : Trial save search
Outlook on the Neurology Clinical Trials Global Market to 2028 - Size, Share & Trends Analysis Report
Published: 2021-11-02 (Crawled : 19:00) - prnewswire.com
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: -2.61%
clinical trials trials trial
Photo Release — Ingalls Shipbuilding Successfully Completes Builder’s Trials for Amphibious Transport Dock Fort Lauderdale (LPD 28)
Published: 2021-11-02 (Crawled : 19:00) - globenewswire.com
HII | $268.84 -0.88% -0.68% 270K
|
Electronic Technology
|
| O: 0.34%
H: 0.0%
C: -1.42%
trials trial
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published: 2021-11-02 (Crawled : 18:00) - biospace.com/
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.0%
H: 4.48%
C: -4.23%
diabetes phase 2 results topline nash trial phase 2b
Global Industrial Lead-Acid Battery Market Sourcing and Procurement Intelligence Report| Top Spending Regions and Market Price Trends| SpendEdge
Published: 2021-11-02 (Crawled : 17:00) - prnewswire.com
ENS | $90.2 0.87% 0.0% 260K
|
Producer Manufacturing
|
| O: 0.24%
H: 0.33%
C: 0.3%
battery trial
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
Published: 2021-11-02 (Crawled : 17:00) - biospace.com/
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: -0.63%
H: 9.62%
C: 8.29%
huntington disease treatment test positive trial huntington’s disease
Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Published: 2021-11-02 (Crawled : 14:00) - biospace.com/
ANVS | $9.85 9.57% 0.96% 240K
|
Health Technology
|
| O: -0.54%
H: 12.67%
C: 11.73%
disease alzheimer clinical trials trials trial conference alzheimer’s alzheimer's disease alzheimer's
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
ALDX 4 | $3.99 0.5% 0.5% 430K
|
Health Technology
|
| O: -0.43%
H: 0.97%
C: -4.65%
dry eye disease phase 2 eye ocular eye disease trial mask
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
GLTO | $0.7077 4.94% 4.71% 110K
|
Health Technology
|
| O: 2.71%
H: 1.76%
C: 0.88%
gb1211 phase 2 lung cancer collaboration cancer trial
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
ABOS | $3.18 -8.36% -9.12% 640K
|
Professional, Scientific, and T...
|
| O: -4.4%
H: 8.83%
C: -1.17%
disease alzheimer clinical trials phase 1 trials trial conference alzheimer’s alzheimer's disease alzheimer's designation
Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3275 -3.56% -3.69% 1.2M
|
|
| O: -27.31%
H: 22.79%
C: 20.28%
phase 2 results trial topline als
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.